Introduction:
Leading pharma company has secured approval from China’s National Medical Products Administration (NMPA) to export its Loratadine API. This milestone strengthens its global presence and unlocks significant opportunities in one of the world’s largest pharmaceutical markets.
Also Read: Engineering stock receives order worth ₹762.56 Cr from Central Railway for Kavach
Share price movement of Morepen Laboratories:
On April 1, 2025, Morepen Laboratories Ltd opened at ₹47.90, up 0.10% from its previous close of ₹47.85. The stock reached a high of ₹49.42 (3.27%) and a low of ₹47.81. By 10:04 AM, it traded at ₹49.18, a 2.78% increase, with a market cap of ₹2,694.84 crore.
Morepen Secures Loratadine Approval for Export to China:
Morepen Laboratories Limited has received approval from China’s National Medical Products Administration (NMPA) for its Loratadine API. This milestone allows Morepen to expand into China, one of the world’s largest pharmaceutical markets.
With an 80% market share in the US generics market for Loratadine, Morepen has been a dominant player in API manufacturing. The company has exported to the US for over 25 years, with API exports valued at ₹650 crore.
The approval strengthens Morepen’s global leadership in Loratadine production. As a widely used antihistamine for allergies, Loratadine’s entry into China positions Morepen to capture a major market share and enhance its global pharmaceutical presence.
Stock performance of Morepen Laboratories for Period of 1 week, 6 months, and 1 year:
Morepen Laboratories Ltd delivered a -3.51% return over the past week, declining by 43.6% in the past six months. The stock gained 5.26% over the past year.
Also Read: Defence stock to watch after it signs contract worth ₹62,700 Cr with Min. of Defence
Shareholding pattern of Morepen Laboratories:
| Particulars | Dec 2024 | Sep 2024 | Jun 2024 |
| Promoter | 35.70% | 35.70% | 38.20% |
| FII | 2% | 2% | 2% |
| DII | 2% | 2% | 2% |
| Public | 60.50% | 60.60% | 58.00% |
About Morepen Laboratories:
Morepen Laboratories Ltd (NSE: MOREPENLAB) manufactures and markets a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and Home Health products, strengthening its presence in the global pharmaceutical and healthcare industry.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
